Tweet

Session 303
Benefits to Academia and Industry of Diverse Strategic Alliances Based on Platform Technologies

Cancer Research UK has established two strategic alliances with AstraZeneca both involving platform technologies. CRUK AstraZeneca Antibody Alliance Laboratory focuses on developing diagnostic and therapeutic antibodies using AstraZeneca's world class antibody drug discovery capability, and Functional Genomics Centre using state of the art CRISPR technology to support target identification and validation.

The presentation and discussion will focus on benefits of both alliances particularly the value proposition supporting the academic ecosystem to help translate novel science, and ability to take on higher risk projects that pharma would not traditionally consider.

Panelists will share how the models came about and how they operate in standalone laboratories with strong matrix management involving CRUK employees and lab heads seconded from AstraZeneca.

Take-aways will include:

Speakers:

Julie Little, CA-AM, RTTP
Strategic Alliance Executive
Cancer Research UK

Julie joined the business development team of what is now Cancer Research UK Commercial Partnerships in 2012 and is now a Strategic Alliance Executive with responsibility for a portfolio of drug discovery partnerships with industry. Commercial Partnerships, formerly known as Cancer Research Technology, develops and commercialises exciting new discoveries in cancer research. Julie has played major roles in establishing CRUK's alliance with Merck Healthcare KGaA, the recently announced partnership with Abcam, and the CRUK-AstraZeneca Antibody Alliance Laboratory whose mission is to collaborate with academics to translate novel science into antibody therapeutics and diagnostics for cancer patient benefit.

Before moving into business development and alliance management Julie was a research scientist at Unilever and Genzyme for a total of almost 25 years. At Genzyme she led the antibody phage display team developing therapeutic antibodies for a range of indications, and developed anti-idiotypic antibodies to aid clinical trials of the now approved multiple sclerosis antibody, Lemtrada.

Kristina Tubby, PhD, CA-AM
Strategic Alliance Manager
Cancer Research UK

Kristina is a Strategic Alliance Manager at Cancer Research UK. She joined CRUK in 2015 after completing her PhD in Developmental Biology at UCL. On joining CRUK, Kris worked in the Strategic Partnerships team identifying, developing and establishing research partnerships with other non-profit organisations. In 2019, Kris joined CRUK's Commercial Partnerships team as a Strategic Alliance Manager and supports the delivery of CRUK's alliances with industry partners. Kris has played a key role in establishing the Joint AZ-CRUK Functional Genomics Centre and continues to be responsible for the management of CRUK business activities within the FGC.

David Andrews, PhD, FRSC
Pre-clinical Director, External R&D and Strategic Alliances
AstraZeneca

Dr. David Andrews trained as a pharmacist at Nottingham University and then undertook PhD research in organic synthesis at Liverpool University. From 1990-2003, he held positions of increasing seniority in medicinal chemistry at GlaxoSmithKline. In 2003, he joined AstraZeneca Early Oncology Chemistry where he led projects delivering the development candidates AZD4547, AZD9496 and AZD0364. Scientifically, David’s current main interests lie in Oncology, with around 60 publications and patents that span cancer and infection medicinal chemistry as well as synthetic chemistry and Open Innovation.He is currently Pre-clinical Director, External R&D and Strategic Alliances, accountable for a large portfolio of Discovery-phase project collaborations including the AstraZeneca CR-UK Functional Genomics Centre.